Pharming Group N.V. (PHAR)

Market Cap	500.38M
Revenue (ttm)	285.75M
Net Income (ttm)	-17.82M
Shares Out	517.00M
EPS (ttm)	-0.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,344
Open	7.50
Previous Close	7.71
Day's Range	7.46 - 7.68
52-Week Range	6.65 - 13.20
Beta	0.81
Analysts	Strong Buy
Price Target	33.50 (+336.2%)
Earnings Date	Oct 24, 2024

About PHAR

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kẟ inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-1...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1988
• Employees: 382
• Stock Exchange: NASDAQ
• Ticker Symbol: PHAR
• Website: https://www.pharming.com

Analyst Forecast

According to 2 analysts, the average rating for PHAR stock is "Strong Buy." The 12-month stock price forecast is $33.5, which is an increase of 336.20% from the latest price.

Price Target

$33.5

(336.20% upside)

Analyst Consensus: Strong Buy